Multi-provincial Cohort for Hypertension (MUCH)

January 21, 2020 updated by: Beijing Institute of Heart, Lung and Blood Vessel Diseases

Multi-provincial Cohort for Hypertension in China

The purpose of this study is to construct hypertension specialized cohort using uniform standards and specifications. This study timely collected multi-dimensional clinical information through electronic medical records, mobile health, data integration, informatics and computer modern techniques, linking self-reported data and big data platforms from different sources to timely obtain the incidence and mortality data, and integrating hypertension cohort samples and the associated clinical records systematically, in order to build a 30-thousand hypertension specialized cohort with fine phenotypic data and blood/urine samples, thus far to provide support for the development of precise medicine research and related industries.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

30000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Beijing, China
        • Recruiting
        • Beijing Anzhen Hospital
      • Beijing, China
        • Recruiting
        • Beijing Tiantan Hospital
        • Contact:
          • Caixia Guo
      • Beijing, China
        • Recruiting
        • Beijing Tsinghua Chang Gung Hospital
        • Contact:
          • Fang Liu
      • Chongqing, China
        • Recruiting
        • Southwest Hospital, China
        • Contact:
          • Xinghua Zhang
      • Guangzhou, China
        • Active, not recruiting
        • Nanfang Hospital of Southern Medical University
      • Shanghai, China
        • Active, not recruiting
        • Ruijin Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

primary care clinic, and community sample

Description

Inclusion Criteria:

  • Clinical diagnosis of hypertension
  • over 18 years old
  • ti sign the informed consent

Exclusion Criteria:

  • with life-threatening severe disease, such as severe tumor or AIDs
  • pregnancy or lactating women,or plan to pregnant within half a year,
  • with severe mental disorders
  • participating in clinical trials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Hospital based hypertension cohort
Drug: Antihypertensive Agents
Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Other: Cardiovascular risk factors
Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
Community based hypertension cohort
Drug: Antihypertensive Agents
Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
Other: Cardiovascular risk factors
Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite end point of major cardiovascular and cerebrovascular events
Time Frame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Composite end point of major cardiovascular and cerebrovascular events
From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
New-onset of cardiovascular events
Time Frame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
New-onset of cardiovascular events
From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
New-onset of stroke
Time Frame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
New-onset of stroke
From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Total death
Time Frame: From date of enrollment until date of death from all cause, assessed up to 3 year
Total death
From date of enrollment until date of death from all cause, assessed up to 3 year
Major bleeding
Time Frame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Major bleeding
From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Atrial fibrillation
Time Frame: From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year
Atrial fibrillation
From date of enrollment until date of first documented event or date of death from cardiovascular and cerebrovascular events, whichever came first, assessed up to 3 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Collaborators

Beijing Tiantan Hospital
Southwest Hospital, China
Nanfang Hospital of Southern Medical University
Ruijin Hospital
Beijing Tsinghua Chang Gung Hospital

Investigators

  • Principal Investigator: Jing Liu, MD,PhD, Beijing Institute of Heart, Lung and Blood Vessel Diseases

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 3, 2017

Primary Completion (Anticipated)

December 1, 2020

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

May 4, 2017

First Submitted That Met QC Criteria

May 10, 2017

First Posted (Actual)

May 12, 2017

Study Record Updates

Last Update Posted (Actual)

January 22, 2020

Last Update Submitted That Met QC Criteria

January 21, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016YFC0900902

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Antihypertensive Agents

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe